New hope for kids with rare sleep epilepsy?

NCT ID NCT04625101

Completed Disease control Sponsor: Neurocrine Biosciences Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study tested a drug called NBI-827104 in 24 children with a rare epilepsy that causes constant brain spikes during sleep. The drug is a calcium channel blocker given daily for 13 weeks. The main goal was to see if it reduces abnormal brain activity measured by EEG.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NBI-827104 (a calcium channel blocker)
What this could lead to: If it works, this could point toward a new treatment to reduce seizure-like brain activity during sleep in children with this rare epilepsy.
What could go wrong: This is a small, early-phase trial with only 24 participants. The drug may not improve symptoms or could cause side effects. Results may not apply to all children.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CONTINUOUS SPIKE AND WAVE DURING SLEEP are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

developmental and epileptic encephalopathy developmental and/or epileptic encephalopathy with spike-wave activation in sleep

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CONTINUOUS SPIKE AND WAVE DURING SLEEP EPILEPTIC ENCEPHALOPATHY

Contacts and locations

Locations

Neurocrine Clinical Site

Orange, California, 92868, United States
Neurocrine Clinical Site

Aurora, Colorado, 80045, United States
Neurocrine Clinical Site

Washington D.C., District of Columbia, 20010, United States
Neurocrine Clinical Site

Miami, Florida, 33155, United States
Neurocrine Clinical Site

Rochester, Minnesota, 55905, United States
Neurocrine Clinical Site

Durham, North Carolina, 27710, United States
Neurocrine Clinical Site

Cleveland, Ohio, 44195, United States
Neurocrine Clinical Site

Philadelphia, Pennsylvania, 19104, United States
Neurocrine Clinical Site

Calgary, Alberta, T3B 6A8, Canada
Neurocrine Clinical Site

Dianalund, 4293, Denmark
Neurocrine Clinical Site

Barcelona, 08950, Spain
Neurocrine Clinical Site

Madrid, 28034, Spain
Neurocrine Clinical Site

Basel, 4031, Switzerland
Neurocrine Clinical Site

Zurich, 8032, Switzerland
Neurocrine Clinical Site

London, WC1N 3JH, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.